Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Posters

Search Title by author or title

Factors predicting successful customised excimer laser treatment in irregular cornea

Poster Details

First Author: R.Hanna ISRAEL

Co Author(s):    M. Mimouni   A. Plaza   J. Alió              

Abstract Details

Purpose:

To identify factors associated with a successful wavefront-guided customized treatment (WG-CT) with excimer laser in highly aberrated corneas.

Setting:

VISSUM, Alicante (Alicante, Spain).

Methods:

Retrospective, consecutive non comparative case series. Treatment was performed with the WG-CT Amaris excimer laser using ORK-CAM software for the calculation of the ablation profile. Included were eyes of patients with significantly aberrated corneas, including post refractive and keratoplasty procedures or high irregular astigmatism with significant high order aberrations (HOAs) that underwent WG-CT. Refractive, HOAs, and visual outcomes were recorded. Statistical analysis was performed to identify factors associated with technical (based on HOAs) or refractive outcome success.

Results:

Overall, 55 treatments of 51 eyes of 35 patients were included.The postoperative uncorrected distance visual acuity (UDVA) was 0.2 logMAR or better in 72% of the eyes, and the postoperative residual manifest refraction spherical equivalent (MRSE) was ±0.50 diopter in 56% the eyes. Successful reduction in HOAs occurred in 36 eyes (65%), and these eyes had significantly higher preoperative HOAs (1.45±0.93μ versus 0.91±0.34 μ, p=0.003) and preoperative coma like aberrations (1.09±0.83μ versus 0.55±0.28μ, p=0.001). In multivariate analysis, post hyperopic treatment eyes were less likely to achieve refractive outcome success (OR=0.09, p=0.02).

Conclusions:

WG-CT in highly aberrated corneas had a limited refractive predictability. Eyes with preoperative coma like aberrations are more likely to benefit from a reduction in HOA. Post hyperopic treatment are associated with a higher rate of refractive surprises.

Financial Disclosure:

None

Back to Poster listing